Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

12.72
-0.2400-1.85%
Post-market: 12.720.00000.00%16:01 EDT
Volume:2.91M
Turnover:37.47M
Market Cap:2.27B
PE:-7.89
High:13.21
Open:12.80
Low:12.65
Close:12.96
52wk High:17.32
52wk Low:2.67
Shares:178.73M
Float Shares:97.65M
Volume Ratio:0.77
T/O Rate:2.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6113
EPS(LYR):-1.6113
ROE:-41.12%
ROA:-25.35%
PB:4.01
PE(LYR):-7.89

Loading ...

Top Relay Therapeutics Executives Quietly Unload Shares in Coordinated Move

TIPRANKS
·
Yesterday

Relay Therapeutics to report first-quarter results after market close

Reuters
·
Apr 30

Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

GlobeNewswire
·
Apr 30

Relay Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $25 From $19

THOMSON REUTERS
·
Apr 29

Relay Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Apr 28

Oppenheimer Adjusts Relay Therapeutics Price Target to $18 From $14, Maintains Outperform Rating

MT Newswires Live
·
Apr 28

Relay Therapeutics : Oppenheimer Raises Target Price to $18 From $14

THOMSON REUTERS
·
Apr 28

Relay Therapeutics price target raised to $21 from $17 at Wells Fargo

TIPRANKS
·
Apr 28

Relay Therapeutics price target raised to $19 from $17 at Citizens

TIPRANKS
·
Apr 28

Barclays Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)

TIPRANKS
·
Apr 28

Relay Therapeutics Inc : Raymond James Raises Target Price to $23 From $19

THOMSON REUTERS
·
Apr 28

Analysts Offer Insights on Healthcare Companies: Cormedix (CRMD) and Relay Therapeutics (RLAY)

TIPRANKS
·
Apr 28

Relay Therapeutics advances zovegalisib combo in breast cancer

TIPRANKS
·
Apr 27

Relay Therapeutics’ combination for breast cancer shows efficacy and safetyPfizer

TIPRANKS
·
Apr 27

Relay Therapeutics plans Phase 3 trial of zovegalisib-atirmociclib triplet in breast cancer

Reuters
·
Apr 27

Relay Therapeutics Inc - Enters Supply Agreement With Pfizer for Atirmociclib in Phase 3 Trial

THOMSON REUTERS
·
Apr 27

Relay Therapeutics Inc - Reports 44% Orr in Heavily Pre-Treated Cdk4/6-Experienced Breast Cancer Patients

THOMSON REUTERS
·
Apr 27

Relay Therapeutics Initiated at Hold by Jones Trading

Dow Jones
·
Apr 14

Relay Therapeutics Inc : Jonestrading Initiates Coverage With Hold Rating; Target Price $18

THOMSON REUTERS
·
Apr 14

Relay Therapeutics initiated with a Hold at JonesResearch

TIPRANKS
·
Apr 14